Increased Incidence of Giant Cell Arteritis After Introduction of a Live Varicella Zoster Virus Vaccine.
giant cell arteritis
live attenuated varicella zoster vaccine
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
10
09
2020
accepted:
28
12
2020
entrez:
18
2
2021
pubmed:
19
2
2021
medline:
19
2
2021
Statut:
epublish
Résumé
Varicella zoster virus (VZV) has been associated with giant cell arteritis (GCA). The introduction of a live attenuated vaccine against this virus (ZVL) might have changed the incidence of GCA. The incidence of GCA was retrospectively measured using 2 matched cohorts seen in a regional health system located in the Midwestern United States: ZVL recipients from the years 2007 through 2015 following the introduction of the vaccine and nonrecipients from the years 2000 through 2015. In the ZVL cohort, a significant increase of GCA was associated with clinical criteria alone for the diagnosis of GCA (hazard ratio [HR], 2.70; 95% CI, 1.48-4.45; Using a matched cohort, retrospective comparison, ZVL was associated with an increased incidence of GCA.
Sections du résumé
BACKGROUND
BACKGROUND
Varicella zoster virus (VZV) has been associated with giant cell arteritis (GCA). The introduction of a live attenuated vaccine against this virus (ZVL) might have changed the incidence of GCA.
METHODS
METHODS
The incidence of GCA was retrospectively measured using 2 matched cohorts seen in a regional health system located in the Midwestern United States: ZVL recipients from the years 2007 through 2015 following the introduction of the vaccine and nonrecipients from the years 2000 through 2015.
RESULTS
RESULTS
In the ZVL cohort, a significant increase of GCA was associated with clinical criteria alone for the diagnosis of GCA (hazard ratio [HR], 2.70; 95% CI, 1.48-4.45;
CONCLUSION
CONCLUSIONS
Using a matched cohort, retrospective comparison, ZVL was associated with an increased incidence of GCA.
Identifiants
pubmed: 33598502
doi: 10.1093/ofid/ofaa647
pii: ofaa647
pmc: PMC7875324
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofaa647Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
J Neurol Sci. 2017 Apr 15;375:158-159
pubmed: 28320119
Future Virol. 2011 Mar;6(3):341-355
pubmed: 21695042
J Infect Dis. 2018 Sep 22;218(suppl_2):S107-S112
pubmed: 30247600
J Infect Dis. 2018 Sep 22;218(suppl_2):S127-S133
pubmed: 30247592
J Med Virol. 2008 Mar;80(3):501-5
pubmed: 18205226
J Infect Dis. 2015 Jul 15;212 Suppl 1:S37-9
pubmed: 26116729
Neuroophthalmology. 2019 Jul 2;43(3):159-170
pubmed: 31312240
Am J Ophthalmol. 2018 Mar;187:51-60
pubmed: 29294312
Clin Infect Dis. 2020 Jun 24;71(1):22-29
pubmed: 31436814
Immunol Rev. 2012 Jan;245(1):189-208
pubmed: 22168421
Arthritis Rheum. 1990 Aug;33(8):1122-8
pubmed: 2202311
Ann Rheum Dis. 2005 May;64(5):780-2
pubmed: 15834059
Clin Infect Dis. 2001 May 15;32(10):1481-6
pubmed: 11317250
JAMA Neurol. 2015 Nov;72(11):1281-7
pubmed: 26349037
J Neurovirol. 2019 Feb;25(1):137-140
pubmed: 30478796
Curr Opin Rheumatol. 2016 Jul;28(4):376-82
pubmed: 27224742